Please ensure Javascript is enabled for purposes of website accessibility

Biogen Inc Earnings Explode Higher, Revenue Not So Much

By Brian Orelli, PhD - Apr 22, 2016 at 6:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Revenue at biotech isn't increasing as fast though.

Biogen (BIIB -0.09%) reported earnings on Thursday with revenue that fell short of expectations, but the biotech was able to cut enough costs to produce a substantial increase in earnings.

Biogen results: The raw numbers

 

Q1 2016 Actuals

Q1 2015 Actuals

Growth (YOY)

Revenue

$2,727 million

$2,555 million

7%

Income From Operations

$1,378 million

$1,118 million

23%

Earnings Per Share

$4.43

$3.49

27%

What happened with Biogen this quarter?

  • Image source: Biogen.

    Top-selling Tecfidera saw sales up 15% year over year, but sales decreased 5% quarter over quarter. The sequential drop was expected because there was an increase in inventory in the fourth quarter of 2015 that was drawn down in the first quarter, but it's still clear that growth in sales of the multiple sclerosis medication is waning.
  • Sales of interferons -- Biogen's older Avonex and newer Plegridy -- decreased 11% year over year as multiple sclerosis patients prefer oral medications such as Tecfidera, Sanofi's (SNY -0.78%) Aubagio, and Novartis' (NVS -0.74%) Gilenya to injected interferons.
  • If you look at Biogen's entire multiple sclerosis franchise, including Tysabri and Fampyra, sales were up 2.4% year over year, which isn't particularly great. It appears that, while Tecfidera is still growing, Biogen is losing overall multiple sclerosis market share to Novartis, which reported a 12% increase in sales of Gilenya. Sanofi is scheduled to report first-quarter results on April 29, so we'll have to wait until then to see how Aubagio is performing.
  • The launch of Biogen's hemophilia drugs are still going well, with Aprolix and Eloctate growing 74% and 101% year over year, respectively. Unlike most of Biogens' drugs, sales of the pair were up quarter over quarter as well, but they remain a small portion of Biogen's product sales, and therefore, their growth doesn't move the revenue needle much.
  • Cost-cutting measures put in place last year are taking effect with selling, general, and administrative costs dropping 11% year over year. Research and development costs also fell year over year, which also helped the bottom line, but management noted that the decrease was due to a lack of acquisitions and licensing deals, and R&D spending will likely go up in future quarters.

What management had to say
Recent articles have claimed Biogen is looking for a buyer for its hemophelia business, but CEO George Scangos wasn't willing to confirm or deny the rumor: "Like you, we read the media reports about our hemophilia business and the subsequent analyst reports. As a matter of policy, we do not comment on speculation, and will not do so in this instance."

Anti-LINGO, which now has a generic name (opicinumab), remains a transformative event for Biogen, with phase 2 data due in the middle of this year. The hope is that opicinumab can take market share if it can improve multiple sclerosis (MS) patients' functioning. "For many MS patients, [drugs that down-regulate the immune system] don't stop the progression. They slow the progression but they don't stop the progression. And so we believe things like LINGO actually are the types of compounds that could actually transform that market and give it additional vibrancy as we move out through the 2020s," Scangos said.

Looking forward
Beyond opicinumab, Biogen's Alzheimer's disease candidate, aducanumab, has the potential to be transformative for the company. The phase 3 trials continue to enroll patients, but we should get some safety data from a phase 1b trial later this year. Biogen has another Alzheimer's drug, BAN2401, that it licensed from Eisai, but it's further back in the clinic.

Nusinersen, which Biogen is developing with Ionis Pharmaceuticals (IONS -0.67%) for treatment of spinal muscular atrophy, is scheduled to read out two phase 3 trials early next year. Updated phase 2 data presented this week by Biogen and Ionis Pharmaceuticals showed that the babies getting the drug continue to develop. Both Biogen and Ionis Pharmaceuticals have downplayed the possibility for an accelerated approval based on the uncontrolled phase 2 data, but Scangos noted that the companies "need to do everything that we can to minimize the time to see data from the phase 3 trials," suggesting an interim look at the data might be in order.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$36.86 (-0.67%) $0.25
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$202.36 (-0.09%) $0.18
Sanofi Stock Quote
Sanofi
SNY
$55.85 (-0.78%) $0.44
Novartis AG Stock Quote
Novartis AG
NVS
$91.25 (-0.74%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.